DMK PHARMACEUTICALS CORP (DMK) Stock Price, Forecast & Analysis
USA - NASDAQ:DMK - US00547W3079 - Common Stock
DMK Key Statistics, Chart & Performance
The current stock price of DMK is 0.232 USD. In the past month the price decreased by -64.9%.
DMK Latest News, Press Relases and Analysis
DMK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.96 | 935.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.67 | 466.81B | ||
| MRK | MERCK & CO. INC. | 10.32 | 227.17B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.43 | 99.17B | ||
| ZTS | ZOETIS INC | 18.95 | 53.23B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 22.72B | ||
| VTRS | VIATRIS INC | 4.81 | 13.06B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.81 | 11.36B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.78 | 8.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.63 | 4.09B |
Related stock screener links
About DMK
Company Profile
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Company Info
DMK PHARMACEUTICALS CORP
11682 El Camino Real, Suite 300
San Diego CALIFORNIA US
Employees: 11
Phone: 18589972400
DMK PHARMACEUTICALS CORP / DMK FAQ
What does DMK do?
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Can you provide the latest stock price for DMK PHARMACEUTICALS CORP?
The current stock price of DMK is 0.232 USD. The price increased by 0.91% in the last trading session.
Does DMK PHARMACEUTICALS CORP pay dividends?
DMK does not pay a dividend.
What is the ChartMill rating of DMK PHARMACEUTICALS CORP stock?
DMK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for DMK stock?
5 analysts have analysed DMK and the average price target is 1.53 USD. This implies a price increase of 559.48% is expected in the next year compared to the current price of 0.232.
Can you provide the PE ratio for DMK stock?
DMK PHARMACEUTICALS CORP (DMK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.17).
DMK Technical Analysis
DMK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMK. DMK may be in some trouble as it scores bad on both profitability and health.
DMK Financial Highlights
Over the last trailing twelve months DMK reported a non-GAAP Earnings per Share(EPS) of -9.17. The EPS increased by 37.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -248.15% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
DMK Forecast & Estimates
5 analysts have analysed DMK and the average price target is 1.53 USD. This implies a price increase of 559.48% is expected in the next year compared to the current price of 0.232.
For the next year, analysts expect an EPS growth of 64.16% and a revenue growth -68.82% for DMK